vs
波尔公司（BALL）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是波尔公司的1.4倍（$4.7B vs $3.3B），梯瓦制药净利率更高（10.2% vs 6.0%，领先4.2%），波尔公司同比增速更快（16.2% vs 11.4%），波尔公司自由现金流更多（$1.0B vs $1.0B），过去两年梯瓦制药的营收复合增速更高（11.1% vs 7.9%）
波尔公司是全球领先的可持续铝制包装解决方案供应商，为饮料、个护、家居产品领域的品牌提供创新包装产品，同时旗下航空航天板块为政府及商业客户提供先进技术、系统与相关服务，全业务线高度重视环保责任与产品可靠性。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
BALL vs TEVA — 直观对比
营收规模更大
TEVA
是对方的1.4倍
$3.3B
营收增速更快
BALL
高出4.8%
11.4%
净利率更高
TEVA
高出4.2%
6.0%
自由现金流更多
BALL
多$25.0M
$1.0B
两年增速更快
TEVA
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.3B | $4.7B |
| 净利润 | $200.0M | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | 7.2% | 6.4% |
| 净利率 | 6.0% | 10.2% |
| 营收同比 | 16.2% | 11.4% |
| 净利润同比 | 766.7% | 321.7% |
| 每股收益（稀释后） | $0.73 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BALLTEVA
| Q4 25 | $3.3B | $4.7B | ||
| Q3 25 | $3.4B | $4.5B | ||
| Q2 25 | $3.3B | $4.2B | ||
| Q1 25 | $3.1B | $3.9B | ||
| Q4 24 | $2.9B | $4.2B | ||
| Q3 24 | $3.1B | $4.3B | ||
| Q2 24 | $3.0B | $4.2B | ||
| Q1 24 | $2.9B | $3.8B |
净利润BALLTEVA
| Q4 25 | $200.0M | $481.0M | ||
| Q3 25 | $321.0M | $433.0M | ||
| Q2 25 | $215.0M | $282.0M | ||
| Q1 25 | $179.0M | $214.0M | ||
| Q4 24 | $-30.0M | $-217.0M | ||
| Q3 24 | $199.0M | $-437.0M | ||
| Q2 24 | $159.0M | $-846.0M | ||
| Q1 24 | $3.7B | $-139.0M |
毛利率BALLTEVA
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | 17.7% | 49.6% | ||
| Q2 24 | 16.5% | 48.6% | ||
| Q1 24 | 16.6% | 46.4% |
营业利润率BALLTEVA
| Q4 25 | 7.2% | 6.4% | ||
| Q3 25 | 11.6% | 19.7% | ||
| Q2 25 | 8.0% | 10.9% | ||
| Q1 25 | 7.4% | 13.3% | ||
| Q4 24 | 0.2% | -0.7% | ||
| Q3 24 | 7.4% | -1.2% | ||
| Q2 24 | 6.8% | -0.1% | ||
| Q1 24 | 6.8% | -5.7% |
净利率BALLTEVA
| Q4 25 | 6.0% | 10.2% | ||
| Q3 25 | 9.5% | 9.7% | ||
| Q2 25 | 6.4% | 6.8% | ||
| Q1 25 | 5.8% | 5.5% | ||
| Q4 24 | -1.0% | -5.1% | ||
| Q3 24 | 6.5% | -10.1% | ||
| Q2 24 | 5.4% | -20.3% | ||
| Q1 24 | 128.3% | -3.6% |
每股收益（稀释后）BALLTEVA
| Q4 25 | $0.73 | $0.42 | ||
| Q3 25 | $1.18 | $0.37 | ||
| Q2 25 | $0.76 | $0.24 | ||
| Q1 25 | $0.63 | $0.18 | ||
| Q4 24 | $0.23 | $-0.19 | ||
| Q3 24 | $0.65 | $-0.39 | ||
| Q2 24 | $0.51 | $-0.75 | ||
| Q1 24 | $11.61 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $3.6B |
| 总债务越低越好 | $7.0B | — |
| 股东权益账面价值 | $5.4B | $7.9B |
| 总资产 | $19.5B | $40.7B |
| 负债/权益比越低杠杆越低 | 1.29× | — |
8季度趋势，按日历期对齐
现金及短期投资BALLTEVA
| Q4 25 | $1.2B | $3.6B | ||
| Q3 25 | $568.0M | $2.2B | ||
| Q2 25 | $296.0M | $2.2B | ||
| Q1 25 | $449.0M | $1.7B | ||
| Q4 24 | $885.0M | $3.3B | ||
| Q3 24 | $1.4B | $3.3B | ||
| Q2 24 | $1.3B | $2.3B | ||
| Q1 24 | $1.7B | $3.0B |
总债务BALLTEVA
| Q4 25 | $7.0B | — | ||
| Q3 25 | $6.9B | — | ||
| Q2 25 | $6.5B | — | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.5B | — | ||
| Q1 24 | $5.5B | — |
股东权益BALLTEVA
| Q4 25 | $5.4B | $7.9B | ||
| Q3 25 | $5.4B | $7.3B | ||
| Q2 25 | $5.2B | $6.8B | ||
| Q1 25 | $5.5B | $6.3B | ||
| Q4 24 | $5.9B | $5.4B | ||
| Q3 24 | $6.7B | $6.1B | ||
| Q2 24 | $6.9B | $6.4B | ||
| Q1 24 | $7.3B | $7.3B |
总资产BALLTEVA
| Q4 25 | $19.5B | $40.7B | ||
| Q3 25 | $18.7B | $39.9B | ||
| Q2 25 | $18.6B | $40.1B | ||
| Q1 25 | $18.0B | $38.4B | ||
| Q4 24 | $17.6B | $39.3B | ||
| Q3 24 | $18.8B | $41.8B | ||
| Q2 24 | $19.0B | $41.3B | ||
| Q1 24 | $19.9B | $42.8B |
负债/权益比BALLTEVA
| Q4 25 | 1.29× | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | 0.80× | — | ||
| Q2 24 | 0.80× | — | ||
| Q1 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $1.0B | $1.0B |
| 自由现金流率自由现金流/营收 | 31.1% | 21.6% |
| 资本支出强度资本支出/营收 | 5.1% | 3.0% |
| 现金转化率经营现金流/净利润 | 6.05× | 2.41× |
| 过去12个月自由现金流最近4个季度 | $788.0M | $1.1B |
8季度趋势，按日历期对齐
经营现金流BALLTEVA
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $384.0M | $369.0M | ||
| Q2 25 | $332.0M | $227.0M | ||
| Q1 25 | $-665.0M | $-105.0M | ||
| Q4 24 | $500.0M | $575.0M | ||
| Q3 24 | $610.0M | $693.0M | ||
| Q2 24 | $252.0M | $103.0M | ||
| Q1 24 | $-1.2B | $-124.0M |
自由现金流BALLTEVA
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $257.0M | $233.0M | ||
| Q2 25 | $236.0M | $131.0M | ||
| Q1 25 | $-746.0M | $-232.0M | ||
| Q4 24 | $393.0M | $446.0M | ||
| Q3 24 | $493.0M | $545.0M | ||
| Q2 24 | $146.0M | $6.0M | ||
| Q1 24 | $-1.4B | $-248.0M |
自由现金流率BALLTEVA
| Q4 25 | 31.1% | 21.6% | ||
| Q3 25 | 7.6% | 5.2% | ||
| Q2 25 | 7.1% | 3.1% | ||
| Q1 25 | -24.1% | -6.0% | ||
| Q4 24 | 13.6% | 10.5% | ||
| Q3 24 | 16.0% | 12.6% | ||
| Q2 24 | 4.9% | 0.1% | ||
| Q1 24 | -48.7% | -6.5% |
资本支出强度BALLTEVA
| Q4 25 | 5.1% | 3.0% | ||
| Q3 25 | 3.8% | 3.0% | ||
| Q2 25 | 2.9% | 2.3% | ||
| Q1 25 | 2.6% | 3.3% | ||
| Q4 24 | 3.7% | 3.1% | ||
| Q3 24 | 3.8% | 3.4% | ||
| Q2 24 | 3.6% | 2.3% | ||
| Q1 24 | 5.4% | 3.2% |
现金转化率BALLTEVA
| Q4 25 | 6.05× | 2.41× | ||
| Q3 25 | 1.20× | 0.85× | ||
| Q2 25 | 1.54× | 0.80× | ||
| Q1 25 | -3.72× | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.07× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | -0.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BALL
| Transferred Over Time | $2.7B | 82% |
| Transferred At Point In Time | $602.0M | 18% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
